Rationale for stimulator of interferon genes–targeted cancer immunotherapy

European Journal of Cancer

Volumn 75, Issue , 2017, Pages 86-97

  Rivera Vargas, Thaiz ^a,b   Benoit Lizon, Isis ^a,b   Apetoh, Lionel ^a,b,c  

^a Institut Médical de Génétique et d Immunologie   (France)

^b UNIVERSITÉ BOURGOGNE FRANCHE COMTÉ   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Adaptive immunity; Anticancer therapies; Cancer immunotherapy; Danger signal; DNA; Innate immunity; STING

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; DNA; RNA; INTERFERON; MEMBRANE PROTEIN; MPYS PROTEIN, HUMAN;

CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CLINICAL PRACTICE; DENDRITIC CELL; GENE TARGETING; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; MOLECULAR SENSOR; NONHUMAN; PRIORITY JOURNAL; REVIEW; STIMULATOR OF INTERFERON GENE; TUMOR GENE; TUMOR IMMUNITY; TUMOR PROMOTION; ADAPTIVE IMMUNITY; AGONISTS; ANIMAL; CARCINOGENESIS; CELL CYCLE CHECKPOINT; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; METABOLISM; MOUSE; NEOPLASMS; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; CARCINOGENESIS; CELL CYCLE CHECKPOINTS; DENDRITIC CELLS; DNA; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INTERFERONS; MEMBRANE PROTEINS; MICE; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85013124305     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.12.028     Document Type: Review

References (95)

1. [1] Matzinger, P., Tolerance, danger, and the extended family. Annu Rev Immunol 12 (1994), 991–1045.
2. [2] Banchereau, J., Steinman, R.M., Dendritic cells and the control of immunity. Nature 392:6673 (1998), 245–252.
3. [3] Barber, G.N., Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr Opin Immunol 23:1 (2011), 10–20.
4. [4] Desmet, C.J., Ishii, K.J., Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 12:7 (2012), 479–491.
5. [5] Barbalat, R., Ewald, S.E., Mouchess, M.L., Barton, G.M., Nucleic acid recognition by the innate immune system. Annu Rev Immunol 29 (2011), 185–214.
6. [6] Lee, C.C., Avalos, A.M., Ploegh, H.L., Accessory molecules for toll-like receptors and their function. Nat Rev Immunol 12:3 (2012), 168–179.
7. [7] Dubensky, T.W. Jr., Reed, S.G., Adjuvants for cancer vaccines. Semin Immunol 22:3 (2010), 155–161.
8. [8] Aarntzen, E.H., Figdor, C.G., Adema, G.J., Punt, C.J., de Vries, I.J., Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 57:10 (2008), 1559–1568.
9. [9] Kalinski, P., Muthuswamy, R., Urban, J., Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev Vaccines 12:3 (2013), 285–295.
10. [10] Palucka, K., Banchereau, J., Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:4 (2012), 265–277.
11. [11] Schuler, G., Dendritic cells in cancer immunotherapy. Eur J Immunol 40:8 (2010), 2123–2130.
12. [12] Krieg, A.M., Development of TLR9 agonists for cancer therapy. J Clin Invest 117:5 (2007), 1184–1194.
13. [13] Boon, T., Coulie, P.G., Van den Eynde, B.J., van der Bruggen, P., Human T cell responses against melanoma. Annu Rev Immunol 24 (2006), 175–208.
14. [14] Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:3 (1998), 321–327.
15. [15] Speiser, D.E., Baumgaertner, P., Voelter, V., Devevre, E., Barbey, C., Rufer, N., et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 105:10 (2008), 3849–3854.
16. [16] Rosenberg, S.A., Sherry, R.M., Morton, K.E., Scharfman, W.J., Yang, J.C., Topalian, S.L., et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175:9 (2005), 6169–6176.
17. [17] Janssen, E.M., Droin, N.M., Lemmens, E.E., Pinkoski, M.J., Bensinger, S.J., Ehst, B.D., et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434:7029 (2005), 88–93.
18. [18] Filipazzi, P., Pilla, L., Mariani, L., Patuzzo, R., Castelli, C., Camisaschi, C., et al. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res 18:23 (2012), 6485–6496.
19. [19] Melief, C.J., van Hall, T., Arens, R., Ossendorp, F., van der Burg, S.H., Therapeutic cancer vaccines. J Clin Invest 125:9 (2015), 3401–3412.
20. [20] Zitvogel, L., Tesniere, A., Kroemer, G., Cancer despite immunosurveillance: immunoselection and immuno subversion. Nat Rev Immunol 6:10 (2006), 715–727.
21. [21] Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:10 (2014), 1020–1030.
22. [22] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:4 (2015), 320–330.
23. [23] Gurunathan, S., Klinman, D.M., Seder, R.A., DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18 (2000), 927–974.
24. [24] Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., et al. A toll-like receptor recognizes bacterial DNA. Nature 408:6813 (2000), 740–745.
25. [25] Krieg, A.M., Vollmer, J., Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 220 (2007), 251–269.
26. [26] Marshak-Rothstein, A., Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6:11 (2006), 823–835.
27. [27] Ishikawa, H., Barber, G.N., STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455:7213 (2008), 674–678.
28. [28] Ishikawa, H., Ma, Z., Barber, G.N., STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461:7265 (2009), 788–792.
29. [29] Barber, G.N., STING: infection, inflammation and cancer. Nat Rev Immunol 15:12 (2015), 760–770.
30. [30] Unterholzner, L., The interferon response to intracellular DNA: why so many receptors?. Immunobiology 218:11 (2013), 1312–1321.
31. [31] Chen, Q., Sun, L., Chen, Z.J., Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol 17:10 (2016), 1142–1149.
32. [32] Sun, L., Wu, J., Du, F., Chen, X., Chen, Z.J., Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339:6121 (2013), 786–791.
33. [33] Wu, J., Sun, L., Chen, X., Du, F., Shi, H., Chen, C., et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339:6121 (2013), 826–830.
34. [34] Abe, T., Barber, G.N., Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1. J Virol 88:10 (2014), 5328–5341.
35. [35] Kondo, T., Kobayashi, J., Saitoh, T., Maruyama, K., Ishii, K.J., Barber, G.N., et al. DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A 110:8 (2013), 2969–2974.
36. [36] Paludan, S.R., Bowie, A.G., Immune sensing of DNA. Immunity 38:5 (2013), 870–880.
37. [37] Ahn, J., Barber, G.N., Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease. Curr Opin Immunol 31 (2014), 121–126.
38. [38] Lemos, H., Huang, L., McGaha, T.L., Mellor, A.L., Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA. Eur J Immunol 44:10 (2014), 2847–2853.
39. [39] Huang, L., Li, L., Lemos, H., Chandler, P.R., Pacholczyk, G., Baban, B., et al. Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J Immunol 191:7 (2013), 3509–3513.
40. [40] Lemos, H., Mohamed, E., Huang, L., Ou, R., Pacholczyk, G., Arbab, A.S., et al. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Res 76:8 (2016), 2076–2081.
41. [41] Ahn, J., Xia, T., Konno, H., Konno, K., Ruiz, P., Barber, G.N., Inflammation-driven carcinogenesis is mediated through STING. Nat Commun, 5, 2014, 5166.
42. [42] Dunn, G.P., Bruce, A.T., Sheehan, K.C., Shankaran, V., Uppaluri, R., Bui, J.D., et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 6:7 (2005), 722–729.
43. [43] Diamond, M.S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G.P., Archambault, J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208:10 (2011), 1989–2003.
44. [44] Woo, S.R., Fuertes, M.B., Corrales, L., Spranger, S., Furdyna, M.J., Leung, M.Y., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41:5 (2014), 830–842.
45. [45] Sun, W., Li, Y., Chen, L., Chen, H., You, F., Zhou, X., et al. ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization. Proc Natl Acad Sci U S A 106:21 (2009), 8653–8658.
46. [46] Zhong, B., Yang, Y., Li, S., Wang, Y.Y., Li, Y., Diao, F., et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 29:4 (2008), 538–550.
47. [47] Jin, L., Waterman, P.M., Jonscher, K.R., Short, C.M., Reisdorph, N.A., Cambier, J.C., MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals. Mol Cell Biol 28:16 (2008), 5014–5026.
48. [48] Demaria, O., De Gassart, A., Coso, S., Gestermann, N., Di Domizio, J., Flatz, L., et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A 112:50 (2015), 15408–15413.
49. [49] Fuertes, M.B., Kacha, A.K., Kline, J., Woo, S.R., Kranz, D.M., Murphy, K.M., et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 208:10 (2011), 2005–2016.
50. [50] Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41:5 (2014), 843–852.
51. [51] Klarquist, J., Hennies, C.M., Lehn, M.A., Reboulet, R.A., Feau, S., Janssen, E.M., STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J Immunol 193:12 (2014), 6124–6134.
52. [52] Ahn, J., Gutman, D., Saijo, S., Barber, G.N., STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A 109:47 (2012), 19386–19391.
53. [53] Ohkuri, T., Ghosh, A., Kosaka, A., Zhu, J., Ikeura, M., David, M., et al. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res 2:12 (2014), 1199–1208.
54. [54] Sauer, J.D., Sotelo-Troha, K., von Moltke, J., Monroe, K.M., Rae, C.S., Brubaker, S.W., et al. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Immun 79:2 (2011), 688–694.
55. [55] Salcedo, R., Cataisson, C., Hasan, U., Yuspa, S.H., Trinchieri, G., MyD88 and its divergent toll in carcinogenesis. Trends Immunol 34:8 (2013), 379–389.
56. [56] Zhu, Q., Man, S.M., Gurung, P., Liu, Z., Vogel, P., Lamkanfi, M., et al. Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J Immunol 193:10 (2014), 4779–4782.
57. [57] Huber, S., Gagliani, N., Zenewicz, L.A., Huber, F.J., Bosurgi, L., Hu, B., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491:7423 (2012), 259–263.
58. [58] Salcedo, R., Worschech, A., Cardone, M., Jones, Y., Gyulai, Z., Dai, R.M., et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 207:8 (2010), 1625–1636.
59. [59] Ahn, J., Konno, H., Barber, G.N., Diverse roles of STING-dependent signaling on the development of cancer. Oncogene 34:41 (2015), 5302–5308.
60. [60] Burnette, B.C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N.N., Weichselbaum, R.R., et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res 71:7 (2011), 2488–2496.
61. [61] Corrales, L., Gajewski, T.F., Molecular pathways: targeting the stimulator of interferon genes (STING) in the immunotherapy of cancer. Clin Cancer Res 21:21 (2015), 4774–4779.
62. [62] Lau, L., Gray, E.E., Brunette, R.L., Stetson, D.B., DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science 350:6260 (2015), 568–571.
63. [63] Xia, T., Konno, H., Ahn, J., Barber, G.N., Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and with tumorigenesis. Cell Rep 14:2 (2016), 282–297.
64. [64] Lam, A.R., Le Bert, N., Ho, S.S., Shen, Y.J., Tang, M.L., Xiong, G.M., et al. RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma. Cancer Res 74:8 (2014), 2193–2203.
65. [65] Gasser, S., Orsulic, S., Brown, E.J., Raulet, D.H., The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436:7054 (2005), 1186–1190.
66. [66] Ho, S.S., Zhang, W.Y., Tan, N.Y., Khatoo, M., Suter, M.A., Tripathi, S., et al. The DNA structure-specific endonuclease MUS81 mediates DNA sensor STING-dependent host rejection of prostate cancer cells. Immunity 44:5 (2016), 1177–1189.
67. [67] Plowman, J., Narayanan, V.L., Dykes, D., Szarvasi, E., Briet, P., Yoder, O.C., et al. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70:5 (1986), 631–635.
68. [68] Cummings, J., Smyth, J.F., Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours. Cancer Chemother Pharmacol 24:5 (1989), 269–272.
69. [69] Liu, J.J., Ching, L.M., Goldthorpe, M., Sutherland, R., Baguley, B.C., Kirker, J.A., et al. Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemother Pharmacol 59:5 (2007), 661–669.
70. [70] Baguley, B.C., Ching, L.M., Immunomodulatory actions of xanthenone anticancer agents. BioDrugs 8:2 (1997), 119–127.
71. [71] Lara, P.N. Jr., Douillard, J.Y., Nakagawa, K., von Pawel, J., McKeage, M.J., Albert, I., et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29:22 (2011), 2965–2971.
72. [72] Prantner, D., Perkins, D.J., Lai, W., Williams, M.S., Sharma, S., Fitzgerald, K.A., et al. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem 287:47 (2012), 39776–39788.
73. [73] Gao, P., Ascano, M., Zillinger, T., Wang, W., Dai, P., Serganov, A.A., et al. Structure-function analysis of STING activation by c[G(2′,5′)pA(3′,5′)p] and targeting by antiviral DMXAA. Cell 154:4 (2013), 748–762.
74. [74] Kim, S., Li, L., Maliga, Z., Yin, Q., Wu, H., Mitchison, T.J., Anticancer flavonoids are mouse-selective STING agonists. ACS Chem Biol 8:7 (2013), 1396–1401.
75. [75] Conlon, J., Burdette, D.L., Sharma, S., Bhat, N., Thompson, M., Jiang, Z., et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol 190:10 (2013), 5216–5225.
76. [76] Burdette, D.L., Monroe, K.M., Sotelo-Troha, K., Iwig, J.S., Eckert, B., Hyodo, M., et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 478:7370 (2011), 515–518.
77. [77] Chandra, D., Quispe-Tintaya, W., Jahangir, A., Asafu-Adjei, D., Ramos, I., Sintim, H.O., et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol Res 2:9 (2014), 901–910.
78. [78] Wang, Z., Celis, E., STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother 64:8 (2015), 1057–1066.
79. [79] Yi, G., Brendel, V.P., Shu, C., Li, P., Palanathan, S., Cheng Kao, C., Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS One, 8(10), 2013, e77846.
80. [80] Diner, E.J., Burdette, D.L., Wilson, S.C., Monroe, K.M., Kellenberger, C.A., Hyodo, M., et al. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep 3:5 (2013), 1355–1361.
81. [81] Gao, P., Ascano, M., Wu, Y., Barchet, W., Gaffney, B.L., Zillinger, T., et al. Cyclic [G(2′,5′)pA(3′,5′)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell 153:5 (2013), 1094–1107.
82. [82] Li, T., Cheng, H., Yuan, H., Xu, Q., Shu, C., Zhang, Y., et al. Antitumor activity of cGAMP via stimulation of cGAS-cGAMP-STING-IRF3 mediated innate immune response. Sci Rep, 6, 2016, 19049.
83. [83] Abe, T., Harashima, A., Xia, T., Konno, H., Konno, K., Morales, A., et al. STING recognition of cytoplasmic DNA instigates cellular defense. Mol Cell 50:1 (2013), 5–15.
84. [84] Parvatiyar, K., Zhang, Z., Teles, R.M., Ouyang, S., Jiang, Y., Iyer, S.S., et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat Immunol 13:12 (2012), 1155–1161.
85. [85] Zhang, X., Shi, H., Wu, J., Zhang, X., Sun, L., Chen, C., et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell 51:2 (2013), 226–235.
86. [86] Li, L., Yin, Q., Kuss, P., Maliga, Z., Millan, J.L., Wu, H., et al. Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol 10:12 (2014), 1043–1048.
87. [87] Corrales, L., Glickman, L.H., McWhirter, S.M., Kanne, D.B., Sivick, K.E., Katibah, G.E., et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 11:7 (2015), 1018–1030.
88. [88] Fu, J., Kanne, D.B., Leong, M., Glickman, L.H., McWhirter, S.M., Lemmens, E., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med, 7(283), 2015, 283ra52.
89. [89] Moore, E., Clavijo, P.E., Davis, R., Cash, H., Van Waes, C., Kim, Y., et al. Established T cell-inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade. Cancer Immunol Res 4:12 (2016), 1061–1071.
90. [90] Apetoh, L., Smyth, M.J., Drake, C.G., Abastado, J.P., Apte, R.N., Ayyoub, M., et al. Consensus nomenclature for CD8+ T cell phenotypes in cancer. Oncoimmunology, 4(4), 2015, e998538.
91. [91] Rivera Vargas, T., Humblin, E., Vegran, F., Ghiringhelli, F., Apetoh, L., TH9 cells in anti-tumor immunity. Semin Immunopathol 39:1 (January 2017), 39–46.
92. [92] Fridman, W.H., Pages, F., Sautes-Fridman, C., Galon, J., The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:4 (2012), 298–306.
93. [93] Poltorak, A., Kurmyshkina, O., Volkova, T., Stimulator of interferon genes (STING): a “new chapter” in virus-associated cancer research. Lessons from wild-derived mouse models of innate immunity. Cytokine Growth Factor Rev 29 (2016), 83–91.
94. [94] Monroe, K.M., Yang, Z., Johnson, J.R., Geng, X., Doitsh, G., Krogan, N.J., et al. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science 343:6169 (2014), 428–432.
95. [95] Berg, R.K., Rahbek, S.H., Kofod-Olsen, E., Holm, C.K., Melchjorsen, J., Jensen, D.G., et al. T cells detect intracellular DNA but fail to induce type I IFN responses: implications for restriction of HIV replication. PLoS One, 9(1), 2014, e84513.